Invizius

Invizius, an Edinburgh-based biotech company pioneering treatments for dialysis patients, has secured £950,000 in funding. The funding round was led by Mercia Ventures and supported by Calculus Capital, Syensqo, the University of Edinburgh's Old College Capital, and Scottish Enterprise.

Invizius, the University of Edinburgh spin-out which is developing potentially lifesaving products for dialysis patients, has announced the appointment of James Robson as its chief financial officer.

Invizius, the University of Edinburgh spin-out whose technology could help reduce the high death rates amongst dialysis patients, has raised £2.75 million from a consortium of investors. The funding round was led by Mercia and included Downing Ventures, the University’s Old College Capit